Cases & Deals

Onxeo completes €40.7 million rights issue

Clients Onxeo SA

Jones Day represented Onxeo SA, an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, in connection with its €40.7 million (US$50.6 million) issuance of Ordinary Shares. Natixis and Oddo & Cie acted as joint lead managers and joint bookrunners. This was the first simultaneous public offering in France and Denmark.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.